Financials · Investment Advice

CG Carlyle Group 13F Holdings & SEC Filings 2026

fund
CIK 1527166203 filings
S&P 500

CG at a glance

Carlyle Group reported 16 positions worth $8.4 billion in its 13F-HR for Q3 2026, filed November 6, 2026. Its largest holdings were Medline Inc (MDLN) at 77.6%, Standardaero Inc (SARO) at 21.6% and Phathom Pharmaceuticals Inc (PHAT) at 0.3%.

  • Versus Q2 2026, it opened 0 new positions, added to 2, trimmed 1 and sold out of 3. Reported portfolio value went from $10.0 billion to $8.4 billion.
  • The 10 largest positions made up 100.0% of the reported portfolio.
  • Largest estimated buys in Q3 2026: Robinhood Mkts Inc (HOOD) (added, about $454,000) and Ramaco Res Inc (METC) (added, about $258,000).
  • For the fiscal year ended December 31, 2025 (FY2025), Carlyle Group (CG) reported revenue of $4.8 billion (down 11.9% from FY2024) and net income of $808.7 million. Diluted EPS was $2.18.
  • As of September 30, 2026, 35 institutional investment managers tracked by SignalX reported holding Carlyle Group (CG) shares worth $3.7 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Rubenstein David M. on September 11, 2026 of 400,000 shares at $42.74 per share.
  • In the last 90 days, CG insiders reported 0 open-market purchases ($0) and 1 open-market sale ($17.1M) on Form 4, a net sale of $17.1M.

Source: 13F-HR filings on SEC EDGAR.

13F portfolio · Q3 2026
$8.4B
−16.4% vs prior quarter
Positions
16
0 new · 3 sold out
Top 10 weight
100.0%
Concentration of the 13F book
Turnover
0%
Quarter-over-quarter
Revenue · FY2025
$4.8B
−11.9% vs prior year
13F holders
35 funds
$3.7B · −1 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

Carlyle Group top 13F holdings, Q3 2026

Largest reported positions by market value, from the 13F-HR filed Nov 6, 2026

Carlyle Group 13F holdings for Q3 2026
#CompanyWeightValueSharesvs Q2 2026
1Medline IncMDLN77.64%$6.5B187,083,713Held
2Standardaero IncSARO21.60%$1.8B84,587,035Held
3Phathom Pharmaceuticals IncPHAT0.30%$25.5M3,496,808Held
4Pony Ai IncPONY0.18%$15.4M2,362,447Held
5Invitation Homes IncINVH0.15%$12.6M477,500Trimmed
6Spruce Biosciences Inc0.02%$1.9M38,620Held
7Forward Air Corp0.02%$1.6M107,214Held
8Adicet Bio IncACET0.02%$1.3M184,295Held
9Robinhood Mkts IncHOOD0.01%$986K8,767Added
10Krispy Kreme IncDNUT0.01%$978K340,748Held
11Onkure Therapeutics Inc0.01%$735K269,895Held
12SunPower Inc0.01%$720K2,343,750Held
13Jasper Therapeutics Inc0.01%$618K1,066,189Held
14Ramaco Res IncMETC0.01%$438K52,922Added
15Nebius Group N.V.NBIS0.01%$435K1,846Held
16N-able IncNABL0.01%$384K93,732Held

Source: Carlyle Group 13F-HR on SEC EDGAR. Long equity positions only (put and call options excluded); weights are shares of the reported 13F portfolio, not total assets. How 13F filings work

Carlyle Group biggest buys and sells, Q3 2026

Largest estimated position changes versus Q2 2026

Carlyle Group largest 13F position changes in Q3 2026
CompanyMoveEst. flowShares nowWeight now
Getty Images Holdings IncGETYSold out−$5.4M0-
Invitation Homes IncINVHTrimmed−$4.9M477,5000.15%
Q32 Bio IncSold out−$769K0-
Riley Exploration Permian InREPXSold out−$530K0-
Robinhood Mkts IncHOODAdded+$454K8,7670.01%
Ramaco Res IncMETCAdded+$258K52,9220.01%

Estimated flow = change in share count × quarter-end price (0 new, 2 added, 1 trimmed, 3 sold out). 13F reports show holdings on the last day of the quarter, not the trade dates.

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Jun 30, 2026

Management Discussion & Analysis

  • Liabilities $21.0B at June 30, down $1.1B from December 31, 2025
  • Cash and equivalents $1.3B excluding Consolidated Funds
  • Six-month share repurchases 7.9M shares, reducing outstanding shares to 353.4M
  • Unfunded Carlyle fund commitments $4.3B, with $3.4B subscribed by professionals
  • Contingent Abingworth payments up to $130.0M, with $16.1M accrued at June 30, 2026

Risk Factors

  • Share-repurchase authorization reset to $2.0 billion effective February 26, 2026
  • $1,630.9 million repurchase authorization remained as of June 30, 2026
  • 6.6 million shares repurchased during the quarter at disclosed average prices of $46.97 and $44.64

AI summary of the CG 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Carlyle reported third-quarter fiscal 2026 results for the period ended September 30, 2026
  • Detailed financial results and management commentary available in Exhibits 99.1 and 99.2

Item EX-99.1: Item EX-99.1

  • Q3 2026 results: GAAP loss before taxes of $77 million, with a 23.0% margin on loss before taxes
  • Distributable earnings per share described as among Carlyle’s strongest quarters on record

Item EX-99.2: Item EX-99.2

  • Q3 2026 results covered the quarter ended September 30, 2026, with GAAP loss attributable to Carlyle of $8 million, or $0.02 diluted EPS
  • Distributable Earnings reached $433 million, or $1.12 post-tax per share, highlighting stronger cash-oriented earnings despite GAAP losses
Filed Aug 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results for quarter ended June 30, 2026, released August 5, 2026
  • Detailed financial information available in Exhibits 99.1 and 99.2

Item EX-99.1: Item EX-99.1

  • Q2 2026 income before taxes $274 million, with a 24.4% margin
  • Record Fee Related Earnings and highest Distributable Earnings in nearly four years, signaling stronger recurring profitability

Item EX-99.2: Item EX-99.2

  • Q2 2026 earnings release: Distributable Earnings $472M, or $1.07 per share, supporting stronger shareholder returns
  • Fee Related Earnings $358M, up 11% year over year, while FRE margin declined to 47% from 48%
Filed Jun 5, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Carlyle held its 2026 Annual Meeting on June 3, 2026
  • Item 5.02 indicates officer or compensatory-arrangement disclosures, but the provided excerpt is incomplete

Item 5.07: Submission of Matters to a Vote of Security Holders

  • All 13 director nominees elected for one-year terms, with FOR votes ranging from 287.6M to 300.0M
  • Ernst & Young ratified as independent auditor for 2026, receiving 325.3M FOR votes versus 7.4M AGAINST

AI summaries of CG 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CG

Don't miss the next CG filing

  • 13F alerts. A push when CG files a new 13F or a 13D stake.
  • Smart Money consensus. Which stocks CG and other tracked funds bought together.
  • Ask anything. An AI agent that reads every CG filing and answers with sources.

CG alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Nedelman JeffreyFNov 1, 2026$40.18
Rubenstein David M.GSep 11, 2026-
Rubenstein David M.SellSep 11, 2026$42.74
LoBue LindsayAAug 26, 2026-
SCHWARTZ HARVEY MAAug 26, 2026-
Heinzelman Kate ElizabethAAug 26, 2026-
Jenkins Mark DavidAAug 26, 2026-
Nedelman JeffreyAAug 26, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$3.0B$5.4B$4.8B
Net Income-$608.4M$1.0B$808.7M
Net Margin-20.5%18.8%16.9%
Balance Sheet
Total Assets$21.2B$23.1B$29.1B
Equity-$6.3B$7.1B
ROE-16.1%11.5%
Per Share
EPS$-1.68$2.77$2.18
Cash Flow
Operating CF$204.9M-$759.5M-$3.3B
CapEx$66.6M$77.7M$99.4M

Source: XBRL data in Carlyle Group (CG)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CG share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CG shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202635$3.66B
Q2 202636$4.17B
Q1 202635$4.97B
Q4 202532$6.31B
Q3 202532$6.57B
Q2 202531$4.98B
Q1 202527$3.09B
Q4 202428$2.51B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 256 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CG filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest Carlyle Group SEC filings

FormFiling dateAnalysisSEC
13F-HRNov 6, 2026-
8-KNov 5, 2026Analysis-
4Nov 3, 2026--
4Sep 11, 2026--
4Aug 28, 2026--
4Aug 28, 2026--
4Aug 28, 2026--
4Aug 28, 2026--
4Aug 28, 2026--
4Aug 28, 2026--
4Aug 28, 2026--
4Aug 28, 2026--
10-QAug 10, 2026Analysis
13F-HRAug 7, 2026-
8-KAug 5, 2026Analysis-
4Aug 4, 2026--
4Aug 4, 2026--
4Aug 4, 2026--
4Aug 4, 2026--
4Aug 4, 2026--
4Aug 4, 2026--
4Aug 4, 2026--
8-KJun 5, 2026Analysis
8-KJun 1, 2026Analysis
4May 29, 2026-

Related Financials companies

All Financials →

CG 13F holdings: frequently asked questions

What stocks does Carlyle Group own?

In its 13F-HR for Q3 2026 (filed November 6, 2026), Carlyle Group reported 16 positions worth $8.4 billion. The largest were Medline Inc (MDLN), 77.6%; Standardaero Inc (SARO), 21.6%; Phathom Pharmaceuticals Inc (PHAT), 0.3%; Pony Ai Inc (PONY), 0.2%; Invitation Homes Inc (INVH), 0.1%. The top 10 positions were 100.0% of the portfolio.

What did Carlyle Group buy in Q3 2026?

Compared with Q2 2026, Carlyle Group's largest estimated purchases were Robinhood Mkts Inc (HOOD) (added, about $454,000) and Ramaco Res Inc (METC) (added, about $258,000). In total it opened 0 new positions and added to 2. Amounts are estimated from share-count changes at quarter-end prices.

What did Carlyle Group sell in Q3 2026?

Compared with Q2 2026, Carlyle Group's largest estimated sales were Getty Images Holdings Inc (GETY) (sold out, about $5.4 million), Invitation Homes Inc (INVH) (trimmed, about $4.9 million), Q32 Bio Inc (sold out, about $769,000) and Riley Exploration Permian In (REPX) (sold out, about $530,000). In total it sold out of 3 positions and trimmed 1.

When does Carlyle Group file 13F reports?

Carlyle Group's latest 13F-HR was filed November 6, 2026 and covers the quarter ended September 30, 2026. 13F-HR reports are due within 45 days of each quarter-end, so the Q4 2026 report is due by February 14, 2027.

Are CG insiders buying or selling?

In the last 90 days, Carlyle Group (CG) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $17.1 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CG stock?

As of September 30, 2026, the largest Carlyle Group (CG) holders among the 13F filers tracked by SignalX were BlackRock ($1.1 billion), Vanguard Portfolio Management LLC ($464.6 million), Vanguard Capital Management LLC ($451.0 million), Morgan Stanley ($401.7 million), State Street Corp ($397.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CG's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Carlyle Group (CG) reported revenue of $4.8 billion (down 11.9% from FY2024) and net income of $808.7 million. Diluted EPS was $2.18. The figures come from the XBRL data in the 10-K.

What did CG report in its latest 8-K?

Carlyle Group (CG) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Carlyle reported third-quarter fiscal 2026 results for the period ended September 30, 2026.

What are the latest CG SEC filings?

Carlyle Group (CG) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 3, 2026.

What is CG's SEC CIK number?

Carlyle Group (CG)'s SEC Central Index Key (CIK) is 1527166. EDGAR lists every CG filing under that number.

Ask anything about CG

The research agent reads CG's filings, financials, insider trades and 13F holders, then answers with sources.